Endometrial cancer typically responds well to surgical intervention in its initial stages, primarily through hysterectomy, which offers a high chance of remission. However, disseminated or recurrent forms pose a daunting clinical challenge due to the lack of effective molecularly tailored therapies. Conventional chemotherapies and radiation therapies tend to fall short either by limited efficacy or significant toxicity. Hence, the integration of molecular imaging with targeted agents—theranostics—stands as a beacon of hope for improving patient stratification, enabling personalized treatment regimens, and ultimately enhancing survival outcomes.

In pursuit of this goal, the investigative team embarked on an in-depth evaluation of three candidate biomarkers: HER2, mucin-16 (MUC16), and CD24. These antigens were selected based on their reported expression patterns in various cancers and their suitability as targets for molecular imaging and targeted radionuclide therapies. Employing immunohistochemistry and cell-based assays, the researchers assessed their expression in both healthy uterine/endometrial tissues and endometrial cancer-derived cell lines and patient tissues, providing a comprehensive comparative framework to identify differential overexpression amenable to nuclear medicine applications.

Central to this exploration was the generation of specialized immunoPET probes conjugated with Zirconium-89 (^89Zr), a positron-emitting radioisotope favored for its optimal half-life suited to antibody-based imaging. Specifically, ^89Zr-DFO-trastuzumab targeted HER2, ^89Zr-DFO-AR9.6 was directed against MUC16, and ^89Zr-DFO-ATG-031 targeted CD24. The design hinged on the principle that radiolabeled monoclonal antibodies selectively bind to their cognate antigens on tumor cells, enabling precise in vivo visualization and quantification through PET imaging.

Subsequent in vivo investigations utilized mouse models harboring subcutaneous xenografts developed from endometrial cancer cell lines as well as patient-derived xenografts (PDX). These murine models served as robust platforms to evaluate the biodistribution, tumor targeting efficiency, and imaging contrast of the radiotracers. Intriguingly, the CD24-targeted probe ^89Zr-DFO-ATG-031 consistently demonstrated the highest tumor uptake coupled with superior tumor-to-background ratios, highlighting its potential as a front-runner for radiotheranostic applications. Conversely, ^89Zr-DFO-trastuzumab exhibited moderate but nonetheless promising tumor localization, while the MUC16-targeting agent provided suboptimal imaging results, underscoring the heterogeneity of antigen accessibility and probe performance.

Mechanistically, CD24 is a glycosylphosphatidylinositol-anchored cell surface protein implicated in tumor progression and metastasis through modulation of cell adhesion and immune evasion pathways. Its overexpression in aggressive endometrial tumors may render it a valuable biomarker for both imaging and therapeutic intervention. HER2, a well-established oncogenic receptor tyrosine kinase, holds a legacy of clinical relevance in breast and gastric cancers; its emerging role in endometrial cancer introduces possibilities for repurposing trastuzumab-based therapeutic strategies augmented by diagnostic imaging.

The dual capability of these radiolabeled antibodies to identify tumor antigen expression non-invasively while simultaneously serving as vehicles for radionuclide therapy embodies the essence of theranostics—melding diagnostic precision with personalized treatment. PET imaging facilitates the selection of patients who express the target antigen at sufficient levels, thereby optimizing dosing and minimizing off-target effects. Therapeutically, these agents can be modified to deliver cytotoxic radioisotopes, such as alpha or beta emitters, directly to malignant cells, enabling targeted cellular destruction with limited systemic exposure.

Beyond the laboratory, the clinical translation of HER2 and CD24-targeted radiotheranostics bears significant implications. For patients with recurrent or metastatic endometrial cancer who currently face limited options, these strategies may offer new hope in terms of improved detection, therapy guidance, and real-time monitoring of treatment response. Moreover, the utilization of immunoPET probes can streamline drug development pipelines by providing robust biomarkers for therapeutic efficacy, expediting regulatory approvals.

The researchers emphasize that while MUC16 did not demonstrate encouraging imaging properties in this context, the comprehensive evaluation approach establishes a valuable template for future biomarker validation efforts. By integrating molecular biology, radiochemistry, and preclinical imaging, this study charts a course for systematic identification of viable radiotheranostic targets in understudied malignancies beyond the traditional scope.

Dr. Brian M. Zeglis, senior author and noted expert in nuclear chemistry, highlights the novelty and necessity of this approach in endometrial cancer. He stresses that advancing these radiotheranostic probes into clinical trials will require collaborative efforts spanning academia, industry, and regulatory bodies. Nevertheless, the promising preclinical data underscore the transformative potential of molecularly guided nuclear medicine techniques in addressing pressing unmet needs in oncology.

Such investigations align with the broader trend towards precision oncology, where therapeutics are tailored based on individual tumor biology rather than conventional histopathological classification. Leveraging PET imaging with radiolabeled antibodies not only refines diagnosis but also furthers understanding of tumor heterogeneity, receptor dynamics, and resistance mechanisms at a molecular level. This integrative paradigm could pave the way for iterative improvements in patient outcomes through adaptive treatment strategies.

In conclusion, the identification of HER2 and CD24 as robust radiotheranostic targets offers a new frontier in the molecular imaging and treatment of endometrial cancer. The study’s rigorous experimental design, coupled with insightful interpretation of imaging and biodistribution data, positions these molecular targets at the forefront of forthcoming clinical applications. As the quest for effective management of advanced endometrial cancer intensifies, such innovations herald a paradigm shift toward more precise, effective, and personalized nuclear medicine interventions.

Subject of Research: Animals

Article Title: Evaluating Radiotheranostic Targets for Endometrial Cancer

News Publication Date: September 4, 2025

Web References:
https://doi.org/10.2967/jnumed.125.270318

References:
Sebastiano et al., J Nucl Med 2025; jnumed.125.270318

Image Credits:
Sebastiano et al., J Nucl Med 2025; jnumed.125.270318

Keywords:
Cancer treatments, Biomarkers, Cancer

Precision oncology hinges on detecting key genetic mutations that drive tumor growth and response to therapy. Traditionally, tumor tissue biopsies have served as the gold standard for such profiling by directly sampling the tumor. However, tissue biopsies require invasive procedures, and because samples are taken from localized tumor regions, they risk missing the broader spectrum of genetic heterogeneity intrinsic to many cancers. Conversely, liquid biopsies analyze circulating tumor DNA fragments shed into the bloodstream, offering a less invasive alternative that theoretically captures tumor diversity more comprehensively. Yet, their sensitivity is limited by how much tumor DNA enters circulation, potentially leading to incomplete or false-negative genomic profiles.

The ROME trial was designed to rigorously compare outcomes based on genomic profiling concordance between paired tissue and liquid biopsies. Enrolling nearly 1,800 patients with advanced or metastatic solid tumors from multiple centers between late 2020 and mid-2023, the trial mandated that all participants submit samples for both FoundationOne CDx tissue and FoundationOne Liquid CDx assays. These next-generation sequencing (NGS) platforms interrogate hundreds of cancer-associated genes to detect alterations deemed actionable—those with potential targeted therapies—via a molecular tumor board’s expert analysis.

Out of these patients, the tumor board identified 400 individuals harboring actionable genomic alterations. Strikingly, just under half (49.2%) exhibited concordant actionable mutations detected in both tissue and liquid biopsies (the T+L group). Another 34.7% had alterations found exclusively in tissue samples, while 16% had them exclusively in liquid biopsies. This discordance underscores the complexity of tumor biology and the technical limitations of each biopsy method when deployed in isolation.

The survival benefits of guiding therapy using concordant biopsy findings were profound. Patients in the T+L group receiving matched targeted therapy experienced a median overall survival (OS) of 11.05 months, significantly surpassing the 7.7 months observed in patients receiving standard-of-care treatments. This corresponded to a substantial 26% risk reduction in death. Median progression-free survival (PFS) in this group also nearly doubled to 4.93 months versus 2.8 months in controls, reflecting a 45% decrease in disease progression risk. These figures highlight the potency of combining molecular insights across biopsy platforms to more precisely identify therapeutic targets.

In contrast, patients whose actionable alterations were identified through only one biopsy type showed attenuated benefits from tailored therapy. The median OS for those with tissue-only actionable findings was 9.93 months, while those with liquid-only findings fared worst at 4.05 months. Progression-free survival followed a corresponding gradient, further underscoring that concordance between both biopsy methods correlates with superior clinical outcomes, likely due to a more accurate and comprehensive understanding of tumor genomics.

Importantly, the trial also revealed higher objective response rates in the T+L tailored therapy group at 20%, compared with 11.8% among patients receiving standard care. The 12-month OS and PFS rates further reinforced these trends, with nearly half of patients in the concordant group alive after one year and over a quarter free from progression, compared to markedly lower rates in standard-care cohorts. These statistics underpin the clinical relevance and potential practice-changing impact of leveraging concordant molecular profiles.

The molecular tumor board attributed discordance primarily to detection variances—where mutations were seen in one assay but not the other—in 43.3% of cases. Additional causes included high tumor mutational burden (35%), microsatellite instability (1%), and technical issues such as test failures in 21%. Notably, pathways such as PI3K/PTEN/AKT/mTOR and ERBB2 signaling displayed the greatest rates of discordance, suggesting that certain genomic contexts remain challenging to detect consistently across biopsy types.

Dr. Paolo Marchetti, who led the ROME trial analysis, highlighted the implications of these findings for the evolution of precision oncology diagnostics. He pointed out that the presence of the same actionable tumor genomic alterations at different metastatic sites may explain the survival advantage seen with concordant profiling. By expanding analyses to integrate additional clinical variables such as disease subtype, biopsy timing, and metastatic location, future diagnostic algorithms can become more refined and predictive.

The study authors acknowledged important limitations: as an exploratory trial, it lacked predefined power for subgroup analyses, which limits the strength and generalizability of some conclusions. Additionally, tissue and liquid biopsy samples were collected at different time points, reflecting real-world complexities but potentially influencing concordance rates. The relatively smaller size of certain subgroups, particularly the liquid-only cohort, also calls for cautious interpretation.

Looking ahead, the research team advocates for strategies to overcome discordance—including combining additional molecular profiling modalities and enhancing assay sensitivity—to better capture tumor heterogeneity. Plans are underway to validate these findings in larger multicenter cohorts using integrated liquid and tissue profiling at multiple timepoints throughout therapy, aiming to develop more dynamic and adaptable diagnostic protocols.

Marchetti emphasized that addressing the technical and biological challenges of discordance will be essential to fully maximize the benefits of precision oncology, enabling truly personalized treatment strategies that improve clinical outcomes for patients with advanced cancers. The ROME trial thus sets a critical precedent for the future integration of liquid and tissue biopsies in routine clinical decision-making.

The ROME trial was supported by major pharmaceutical stakeholders including Roche, Bristol Myers Squibb, Incyte, Novartis, Pfizer, Takeda, Merck, and Eli Lilly and Company. Dr. Marchetti disclosed consultant and advisory roles with multiple industry partners active in oncology drug development. His commitment exemplifies the collaborative interface between clinical research and pharmaceutical innovation needed to drive forward tailored cancer care.

These groundbreaking results not only reaffirm the importance of genomic profiling in oncology but also underscore the nuanced complexity of tumor heterogeneity and the urgent need to optimize biopsy strategies. As the field moves toward increasingly personalized and adaptive cancer therapies, integrating concordant multi-modal molecular diagnostics promises to reshape standard-of-care paradigms and enhance survival prospects for patients confronting advanced solid tumors.

Subject of Research: Precision oncology through concordant genomic profiling in tissue and liquid biopsies for advanced solid tumors

Article Title: Concordant Genomic Alterations in Tissue and Liquid Biopsies Enhance Survival in Advanced Solid Tumors, ROME Trial Shows

News Publication Date: April 2025

Web References:

• ROME Trial ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT04591431
• AACR Annual Meeting 2025: https://www.aacr.org/meeting/aacr-annual-meeting-2025/

Keywords:

• Tumor tissue
• Biopsies
• Cancer treatments
• Precision oncology
• Liquid biopsy
• Tissue biopsy
• Next-generation sequencing
• Genomic alterations
• Advanced solid tumors
• Molecular profiling
• Targeted therapy
• Tumor heterogeneity